Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
|dc.identifier.citation||Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer. 2018 Dec 4;106:144-59.||en|
|dc.description.abstract||Immune checkpoint blockade has been a pivotal development in the management of advanced non-small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.||en|
|dc.title||Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.||en|
|dc.contributor.department||Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK;||en|
|dc.identifier.journal||Eur J Cancer||en|